Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. develops intranasal foralumab, a fully human anti-CD3 monoclonal antibody, as a clinical-stage biotechnology company focused on neuroinflammatory and neurodegenerative diseases. News for TLSA centers on clinical and preclinical data for intranasal anti-CD3 therapy, including non-active secondary progressive multiple sclerosis, Multiple System Atrophy, Alzheimer’s disease, ALS, Long COVID-associated neuroinflammation, and age-related cognitive decline.
Company updates also cover biomarker work involving CSF proteomics, TSPO-PET and microglial activation, peer-reviewed publications, scientific conference presentations, expanded-access observations, and financing actions such as registered direct offerings of ordinary shares and warrants.
Tiziana Life Sciences (Nasdaq: TLSA) announced an investor webinar on July 30, 2020, at 4:00 p.m. U.S. Eastern, where CEO Kunwar Shailubhai will discuss the company’s development pipeline and milestones. The webinar includes a live Q&A session. Tiziana focuses on innovative therapeutics for oncology, inflammation, and infectious diseases. Key products include TZLS-501, a monoclonal antibody for COVID-19 treatment, and Foralumab, a fully human anti-CD3 mAb aimed at autoimmune diseases.
Tiziana Life Sciences (TLSA), a biotechnology firm, has issued 88,580 new ordinary shares at 93 pence each through the exercise of warrants, generating £82,379 in cash. These shares will be admitted to trading on AIM around July 30, 2020, bringing the total number of ordinary shares to 166,497,593. The new shares rank pari passu with existing shares. Tiziana focuses on developing therapies for oncology, inflammation, and infectious diseases, including its work on Foralumab, an anti-CD3 monoclonal antibody.
Tiziana Life Sciences (Nasdaq: TLSA) announced the appointment of John Brancaccio as a Non-executive Director. With extensive experience in finance within the pharmaceutical and biotechnology sectors, Brancaccio has held significant roles, including CFO positions at various companies. He currently serves on the boards of multiple firms, including Cardiff Oncology, Inc. This appointment comes as Tiziana prepares to advance its clinical programs, including phase 2 studies for its novel treatment for autoimmune diseases, indicating the company's focus on enhancing its leadership team to support future growth.
Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) announced that all resolutions were passed at its Annual General Meeting held on July 16, 2020. The meeting took place at 10:00 a.m. in London and New York. The results of the proxy voting will be made available on the Company’s website. Tiziana focuses on discovering and developing novel therapeutic molecules for oncology and immunology, including milciclib and foralumab, a fully human anti-CD3 monoclonal antibody currently in clinical development for various autoimmune and inflammatory diseases.
Tiziana Life Sciences (NASDAQ: TLSA) has submitted a patent application for Foralumab, a fully human anti-CD3 monoclonal antibody, aimed at enhancing CAR-T therapy's effectiveness for cancer and other diseases. The application presents methods to improve CAR-T expansion and survival either alone or with other co-stimulatory agents. Foralumab's reduced cytokine release may improve safety profiles in T-cell therapies. The company is advancing Foralumab for Crohn's Disease and progressive multiple sclerosis, as well as developing an anti-IL-6 receptor monoclonal antibody for COVID-19 treatment.
Tiziana Life Sciences plc (NASDAQ: TLSA) announced a change in its sponsored Level 3 American Depositary Receipt (ADR) programme. ADR holders will receive 1.5 additional ADRs for each existing ADR held as of the record date, July 27, 2020, instead of the previously stated 2.5. Existing ADRs remain valid without requiring exchange. The register at JPMorgan will close for issuances and cancellations from July 27, 2020, and will reopen on August 4, 2020. Tiziana focuses on developing novel molecules to treat diseases including oncology and autoimmunity.
Tiziana Life Sciences plc (NASDAQ: TLSA) has announced a ratio change in its sponsored Level 3 American Depositary Receipt (ADR) program, transitioning to a 2.5 for 1 forward split. This adjustment, effective July 31, 2020, alters the ratio from five ordinary shares for one ADR to two ordinary shares per ADR. The change will increase the number of ADSs without affecting the underlying shares or their nominal values. Existing ADR holders will receive 2.5 additional ADRs for each ADR held as of July 27, 2020, the record date.
Tiziana Life Sciences (TLSA) announced an upcoming interview with CEO Kunwar Shailubhai on The RedChip Money Report scheduled for July 12, 2020. The interview will discuss the company's development pipeline and milestones, airing on Bloomberg International and other US channels. Tiziana focuses on innovative treatments for cancer and autoimmune diseases, including Foralumab, a monoclonal antibody in clinical development. The company cautions that forward-looking statements are subject to risks and uncertainties that may affect actual results.
Tiziana Life Sciences announced an agreement with STC Biologics for GMP manufacturing of TZLS-501, a monoclonal antibody targeting IL-6 receptors, developed for COVID-19 treatment. Tiziana is also advancing inhalation technology for direct delivery of TZLS-501 into the lungs, potentially enhancing efficacy against the disease. A patent application for this technology was submitted. The company aims to submit an Investigational New Drug (IND) application in Q1 2021, leveraging the dual mechanism of TZLS-501 to block IL-6 signaling and deplete IL-6 levels to mitigate cytokine storms in COVID-19 patients.
Tiziana Life Sciences (Nasdaq: TLSA) announced the United States Patent and Trademark Office granted a patent for its oral administration technology of Foralumab, a fully human anti-CD3 monoclonal antibody. This patent marks a historic development for immunotherapies, enabling non-intravenous treatments for diseases like Crohn’s and Alzheimer’s. The patent encompasses stabilized formulations for oral and nasal administration, enhancing therapeutic options while minimizing traditional administration toxicities. Tiziana plans to advance clinical trials evaluating Foralumab in moderate-to-severe Crohn’s Disease patients.